Ironwood Pharma Regains Nasdaq Compliance
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ironwood Pharma ( (IRWD) ) has provided an announcement.
On August 29, 2025, Ironwood Pharmaceuticals announced it has regained compliance with Nasdaq’s minimum bid price requirement, following a previous notice of non-compliance on May 28, 2025. This compliance ensures the company’s continued inclusion on the Nasdaq Global Select Market, marking a positive development for its market positioning.
The most recent analyst rating on (IRWD) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Ironwood Pharma stock, see the IRWD Stock Forecast page.
Spark’s Take on IRWD Stock
According to Spark, TipRanks’ AI Analyst, IRWD is a Neutral.
Ironwood Pharma’s overall stock score is primarily impacted by its challenging financial performance and valuation concerns. The potential delisting risk due to the Nasdaq deficiency letter further exacerbates the negative outlook. While there are some positive technical signals, they are overshadowed by the financial and corporate event risks.
To see Spark’s full report on IRWD stock, click here.
More about Ironwood Pharma
Ironwood Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative medicines.
Average Trading Volume: 1,771,499
Technical Sentiment Signal: Sell
Current Market Cap: $214.4M
See more data about IRWD stock on TipRanks’ Stock Analysis page.
